31.1 C
Vientiane
Sunday, May 11, 2025
spot_img

Cision PR Newswire

HashKey Exchange Achieves SOC 1 Type 2 and SOC 2 Type 2 Certifications

HONG KONG, May 11, 2025 /PRNewswire/ -- HashKey Exchange, the largest* licensed virtual asset exchange in Hong Kong, today announced that HashKey Custody Services Limited** (abbreviated as "HashKey Exchange") has achieved the SOC 1 Type 2 Certification and SOC 2 Type 2 Certification. The certification reinforces HashKey Exchange's role...

Lecomely Launches AirEdge A3 Multi-styler: Uniquify Your Style with All-in-One Hair Mastery

SHENZHEN, China, May 11, 2025 /PRNewswire/ -- Lecomely, a pioneering beauty brand, revolutionizes personal care...

AWDPI Honored at the United Nations: Empowering Asian Women, Advancing Global Gender Equality

From Paris to New York, AWDPI's mission to empower Asian women earns global recognition...

Abu Dhabi and Japan sign agreements to strengthen partnerships, boost bilateral trade and investments

ABU DHABI, UAE, May 11, 2025 /PRNewswire/ -- An Abu Dhabi economic delegation, led by...

TCL CSOT to Unveil Industry-Leading Display Innovations at SID Display Week 2025

SAN JOSE, Calif., May 11, 2025 /PRNewswire/ -- TCL CSOT, a global leader in...

Aker Horizons ASA: Fourth-quarter results 2024

FORNEBU, Norway, Feb. 13, 2025 /PRNewswire/ -- Aker Horizons ASA (OSE: AKH), a developer of green energy and industry, today announced results for the fourth quarter...

Cloud4C Secures Dual AI Specializations on Microsoft Azure, Strengthening AI Capabilities

SINGAPORE, Feb. 13, 2025 /PRNewswire/ -- Cloud4C, a global leader in AI-driven cloud and cybersecurity services, has achieved two prestigious AI specializations on Microsoft...

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has...

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase...